Jump to content

PeproMene Bio, Inc. A annoncé l'achèvement de la première cohorte de doses et l'ouverture de la deuxième cohorte de doses dans son essai clinique de phase 1 sur le lymphome non hodgkinien à cellules B (B-NHL) avec PMB-CT01 (cellules T BAFFR-CAR)


In The News

Recommended Posts

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now


×
×
  • Create New...